While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially ...

Biogen’s commitment to scientific innovation, quality, and patient-centered solutions ... are currently trading 43.9% below their 52-week high of $268.30, reached on Jan. 3.

SAN FRANCISCO Jan 14 (Reuters) - Biogen (BIIB.O), opens new tab expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business ...

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai Inc. has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “n ...

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. The full ...

Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects Zurzuvae could reach $700 million in global sales by 2034. Next: Access Our New, Shockingly Simple 'Alert System ...

there is still an expectation of some pretty high premiums in the market," he said. The CEO said Biogen has "teams of people" at the healthcare conference this week. At last year's meeting ...